Saturday, July 11, 2026

Drug profile · INN

cefepime

cefepime (EXBLIFEP) is an FDA-listed pharmaceutical active ingredient.

EMA: approved Antiinfectives for systemic use (J01) J01DE51
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — cefepime
Class
Antiinfectives for systemic use (J01)
Route
Patents
0
Programs
6
Data quality
0.83

Quick answer

cefepime (EXBLIFEP) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN cefepime
Brand EXBLIFEP
Therapeutic class Antiinfectives for systemic use (J01)
ATC code J01DE51

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. APHP180596 Phase 3 · PARItec · antibiotic therapy in Sepsis
  2. OP0595-6 Phase 3 · Anaxis Pharma · Complicated urinary tract infection (cUTI), acute uncomplica
  3. APHP221166 Phase 2 · PARItec · gram-negative bacillus pneumonia acquired during mechanical
  4. AB.OH.2025 Approved · George Institute for · Infectious diseases
  5. APHP210085 Approved · PARItec · EA-COPD (with mechanical ventilation, invasive or non-invasi
  6. IRB202101979 -A Approved · BRIGHT MINDS BIOSCIENCES · Pneumonia

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is cefepime?

cefepime (EXBLIFEP) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for cefepime?

EXBLIFEP is a marketed brand name for cefepime. Check FDA Drugs@FDA for the current US label holder and prescribing information.